Herantis' Parkinson's Drug Clears Key FDA Hurdle for Pivotal Trial

ESPOO, FINLAND – June 02, 2026 – In a significant step forward for the treatment of Parkinson's disease, clinical-stage biotechnology company Herantis Pharma has received positive feedback from the U.S. Food and Drug Administration (FDA) for its lead candidate, HER-096. The regulatory endorsement paves the way for a crucial Phase 2a proof-of-concept study, bringing a potential disease-modifying therapy one step closer to reality for millions of patients worldwide.

The announcement signals a major de-risking event for the Finnish company, which has now finalized the study design for the trial. This progress is bolstered by the news that over half of the required funding for this next clinical phase has already been secured or identified, solidifying the program's path forward.

A New Approach to a Degenerative Disease

For decades, the standard of care for Parkinson's disease has been limited to managing symptoms. Current medications primarily work by replenishing dopamine levels in the brain, which can improve motor control but do nothing to halt or slow the underlying neurodegeneration. This leaves a vast unmet medical need for treatments that can modify the course of the disease itself.

Herantis aims to fill this void with HER-096, a first-in-class small peptide. The therapy is engineered to mimic the neuroprotective mechanism of a naturally occurring protein called cerebral dopamine neurotrophic factor (CDNF). Preclinical research has shown that CDNF can protect vital dopamine-producing neurons from cell death and reduce the harmful aggregation of alpha-synuclein, a protein central to Parkinson's pathology.

A key innovation of HER-096 is its ability to cross the formidable blood-brain barrier. This allows for convenient subcutaneous administration, a stark contrast to previous attempts with neurotrophic factors that required direct, invasive delivery to the brain. By targeting the root causes of neuronal decay, HER-096 represents a fundamental shift from symptomatic relief to potentially preserving brain function and slowing disease progression.

Strategic Execution: Securing Regulatory and Financial Backing

The recent feedback from the FDA is a critical milestone that validates Herantis' development strategy. The U.S. agency raised no concerns regarding the company's chemistry, manufacturing, and controls (CMC) or its extensive preclinical data package. The FDA deemed the proposed Phase 2a trial design "appropriate," a significant endorsement that smooths the regulatory pathway. This feedback also confirms that Herantis is in a position to activate U.S. clinical sites for future trials upon submitting an Investigational New Drug (IND) application.

"The successful outcome of our FDA meeting is an important milestone as we advance HER-096 towards Phase 2 development," said Antti Vuolanto, CEO of Herantis Pharma. "Together with our positive Phase 1b data, encouraging biomarker findings and Horizon Europe grant support, the FDA feedback strengthens our confidence in the program and our development strategy."

This regulatory confidence is matched by strong financial footing. The company has secured or identified over 50% of the funds needed for the Phase 2 study. This includes a significant €8 million grant from the Horizon Europe program, awarded to a consortium led by Herantis earlier this year. The company also has a potential investment of up to €15 million from the European Innovation Council (EIC) Fund, underscoring the high level of institutional belief in the program's potential. This blend of non-dilutive grant funding and strategic investment provides a solid financial runway for the upcoming trial while minimizing shareholder dilution.

The Digital Edge: A Modern Trial for a Modern Therapy

The finalized Phase 2a study design itself reflects a forward-thinking approach to clinical research. The randomized, double-blind, placebo-controlled trial will enroll approximately 100 newly diagnosed Parkinson's patients across multiple sites in Europe. Participants, who are not yet receiving symptomatic medication, will be given twice-weekly subcutaneous doses of HER-096 or a placebo for six months, followed by a six-month open-label extension period.

Innovatively, the study's primary endpoint will not be a traditional, subjective clinical scale. Instead, it will use a Digital Motor Score (DMS). This endpoint will be powered by a digital biomarker platform from technology partner Indivi. By using wearable sensors and other digital tools, the platform can provide objective, continuous, and high-frequency data on a patient's motor function in their real-world environment.

This technological integration is a game-changer for neurological trials, which have historically been challenged by the episodic and subjective nature of clinical assessments. Continuous monitoring promises to capture subtle but clinically meaningful changes in disease progression and treatment response that might otherwise be missed. This data-rich approach could provide more robust evidence of HER-096's efficacy and potentially accelerate its development timeline. The trial will also include established clinical assessments, advanced imaging, and biomarker analyses to create a comprehensive picture of the drug's effects. To ensure expert execution, Herantis has appointed CTC Clinical Trial Consultants AB, a clinical research organization with deep experience in Parkinson's trials, to manage the study's operational aspects.

Building on a Foundation of Promising Data

This move into Phase 2 is built upon a solid foundation of earlier clinical success. The Phase 1 program, supported by The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK, successfully demonstrated that HER-096 is generally safe and well-tolerated. Most importantly, it confirmed that the peptide crosses the blood-brain barrier in humans and reaches pharmacologically active concentrations in the cerebrospinal fluid.

Furthermore, biomarker data from the Phase 1b study, reported in January 2026, provided the first evidence of a biological response in patients. The results showed that HER-096 modulated key pathways related to Parkinson's pathology, including proteostasis (the regulation of proteins), mitochondrial function, and neuroinflammation. Seeing these coordinated shifts provides strong scientific rationale that the drug is working as intended.

With the study design finalized, a CRO partner selected, and significant funding in place, Herantis is now focused on initiating the Phase 2a trial. "We look forward to initiating the study and generating data that will further evaluate HER-096's potential as a disease-modifying treatment for Parkinson's disease," Vuolanto added, capturing the sense of momentum and hope that surrounds this promising new therapy.